Diabetic Neuropathy 

  • Author: Helen C Lin, MD; Chief Editor: Nicholas Lorenzo, MD   more...
 
Updated: Nov 1, 2011
 

Background

Neuropathies are characterized by a progressive loss of nerve fiber function. A widely accepted definition of diabetic peripheral neuropathy is "the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after exclusion of other causes."[1]

Neuropathies are the most common complication of diabetes mellitus (DM), affecting up to 50% of patients with type 1 and type 2 DM. In type 1 diabetes mellitus, distal polyneuropathy typically becomes symptomatic after many years of chronic prolonged hyperglycemia. Conversely, patients with type 2 diabetes mellitus may present with distal polyneuropathy after only a few years of known poor glycemic control; sometimes, these patients already have neuropathy at the time of diagnosis. (See Clinical Presentation.)

Neuropathies severely decrease patients' quality of life (QOL). Furthermore, while the primary symptoms of neuropathy can be highly unpleasant, the secondary complications (eg, falls, foot ulcers, cardiac arrhythmias, and ileus) are even more serious and can lead to fractures, amputations, and even death in patients with DM.

Since diabetic neuropathy can manifest with a wide variety of sensory, motor, and autonomic symptoms, a structured list of symptoms can be used to help screen all diabetic patients for possible neuropathy (see History). Physical examination of patients with suspected distal sensory motor or focal (ie, entrapment or noncompressive) neuropathies should include assessments for both peripheral and autonomic neuropathy (see Physical Examination).

Multiple consensus panels recommend the inclusion of electrophysiologic testing in the evaluation of diabetic neuropathy. An appropriate array of electrodiagnostic tests includes both nerve conduction testing and needle EMG of the most distal muscles usually affected. (See Workup.)

Management of diabetic neuropathy should begin at the initial diagnosis of diabetes. The primary care physician needs to be alert for the development of neuropathy—or even its presence at the time of initial diabetes diagnosis—because failure to diagnose diabetic polyneuropathy can lead to serious consequences, including disability and amputation. In addition, the primary care physician is responsible for educating patients about the acute and chronic complications of diabetes (see Patient Education). Patients with diabetic peripheral neuropathy require more frequent follow-up, with particular attention to foot inspection to reinforce the need for regular self-care. (See Treatment Strategies and Management.)

Management of diabetic neuropathy includes 2 approaches: therapies for symptomatic relief and those that may slow the progression of neuropathy. Of all treatments, tight and stable glycemic control is probably the most important for slowing the progression of neuropathy. Many medications are available for the treatment of diabetic neuropathic pain, although most of them are not specifically approved by the United States Food and Drug Administration for this use. Nonpharmacologic treatment includes rehabilitation, which may comprise physical, occupational, speech, and recreational therapy. (See Medication.)

Next

Anatomy

A review of the anatomy of the peripheral nervous system can facilitate understanding of the classification of diabetic peripheral neuropathy. Peripheral neurons can be categorized broadly as motor, sensory, or autonomic.

Motor neurons originate in the central nervous system (CNS) and extend to the anterior horn of the spinal cord. From the anterior horn, they exit the spinal cord (via ventral roots) and combine with other fibers in the brachial or lumbar plexuses and innervate their target organs through peripheral nerves.

Sensory neurons originate at the dorsal root ganglia (which lie outside the spinal cord) and follow a similar course with motor neurons. Sensory neurons are subdivided into categories according to the sensory modality they convey (see the Table below).

Autonomic neurons consist of sympathetic and parasympathetic types. In the periphery, preganglionic fibers leave the CNS and synapse on postganglionic neurons in the sympathetic chain or in sympathetic ganglia.

The smaller fibers are affected first in DM. With continued exposure to hyperglycemia, the larger fibers become affected. Fibers of different size mediate different types of sensation, as shown in the table below.

Table. Subdivisions of Sensory Neurons (Open Table in a new window)

Fiber Type Size Modality Myelination
A-alpha (I)13-20 micrometersLimb proprioceptionYes
A-beta (II)6-12 micrometersLimb proprioception, vibration, pressureYes
A-delta (III)1-5 micrometersMechanical sharp painYes
C (IV)0.2-1.5 micrometersThermal pain, mechanical burning painNo
Previous
Next

Pathophysiology

The factors leading to the development of diabetic neuropathy are not understood completely, and multiple hypotheses have been advanced.[2, 3, 4, 5, 6, 7, 8, 9, 10, 11] It is generally accepted to be a multifactorial process. Development of symptoms depends on many factors, such as total hyperglycemic exposure and other risk factors such as elevated lipids, blood pressure, smoking, increased height, and high exposure to other potentially neurotoxic agents such as ethanol. Genetic factors may also play a role.[12] Important contributing biochemical mechanisms in the development of the more common symmetrical forms of diabetic polyneuropathy likely include the polyol pathway, advanced glycation end products, and oxidative stress.

For more information, see Type 2 Diabetes and TCF7L2.

Polyol pathway

Hyperglycemia causes increased levels of intracellular glucose in nerves, leading to saturation of the normal glycolytic pathway. Extra glucose is shunted into the polyol pathway and converted to sorbitol and fructose by the enzymes aldose reductase and sorbitol dehydrogenase.[13] Accumulation of sorbitol and fructose lead to reduced nerve myoinositol, decreased membrane Na+/K+ -ATPase activity, impaired axonal transport, and structural breakdown of nerves, causing abnormal action potential propagation. This is the rationale for the use of aldose reductase inhibitors to improve nerve conduction.[14]

Advanced glycation end products

The nonenzymatic reaction of excess glucose with proteins, nucleotides, and lipids results in advanced glycation end products (ACE) that may have a role in disrupting neuronal integrity and repair mechanisms through interference with nerve cell metabolism and axonal transport.[15]

Oxidative stress

The increased production of free radicals in diabetes may be detrimental via several mechanisms that are not fully understood. These include direct damage to blood vessels leading to nerve ischemia and facilitation of AGE reactions. Despite the incomplete understanding of these processes, use of the antioxidant alpha-lipoic acid may hold promise for improving neuropathic symptoms.[16, 17, 18]

Related contributing factors

Problems that are a consequence of or co-contributors to these disturbed biochemical processes include altered gene expression with altered cellular phenotypes, changes in cell physiology relating to endoskeletal structure or cellular transport, reduction in neurotrophins, and nerve ischemia.[19] Clinical trials of the best-studied neurotrophin, human recombinant nerve growth factor, were disappointing. With future refinements, however, pharmacologic intervention targeting one or more of these mechanisms may prove successful.

In the case of focal or asymmetrical diabetic neuropathy syndromes, vascular injury or autoimmunity may play more important roles.[20]

Previous
Next

Etiology

Risk factors that are associated with more severe symptoms include the following[21] :

  • Poor glycemic control
  • Advanced age
  • Hypertension
  • Long duration of DM
  • Dyslipidemia
  • Smoking
  • Heavy alcohol intake
  • HLA-DR3/4 phenotype
  • Tall height

Development of symptoms depends on many factors, such as total hyperglycemic exposure and other risk factors such as elevated lipids, blood pressure, smoking, increased height, and high exposure to other potentially neurotoxic agents such as ethanol. Genetic factors may also play a role.[12]

Peripheral neuropathies have been described in patients with primary DM (types 1 and 2) and in those with secondary diabetes of diverse causes, suggesting a common etiologic mechanism based on chronic hyperglycemia. The contribution of hyperglycemia has received strong support from the Diabetes Control and Complications Trial (DCCT).[22]

An association between impaired glucose tolerance and peripheral neuropathy has been construed as further evidence of a dose-dependent effect of hyperglycemia on nerves, although this relationship remains an area of some controversy for type 2 diabetes and prediabetes.[23, 24, 25, 26]

Previous
Next

Epidemiology

United States statistics

A large American study estimated that 47% of patients with diabetes have some peripheral neuropathy.[27] Neuropathy is estimated to be present in 7.5% of patients at the time of diabetes diagnosis. More than half of cases are distal symmetric polyneuropathy. Focal syndromes such as carpal tunnel syndrome (14-30%),[28, 29, 30] radiculopathies/plexopathies, and cranial neuropathies account for the rest. Solid prevalence data for the latter 2 less-common syndromes is lacking.

The wide variability in symmetric diabetic polyneuropathy prevalence data is due to lack of consistent criteria for diagnosis, variable methods of selecting patients for study, and differing assessment techniques. In addition, because many patients with diabetic polyneuropathy are initially asymptomatic, detection is extremely dependent on careful neurologic examination by the primary care clinician. The use of additional diagnostic techniques, such as autonomic or quantitative sensory testing, might result in a higher recorded prevalence.[31, 32]

International statistics

In a cohort of 4400 Belgian patients, Pirart et al found that 7.5% of patients already had neuropathy when diagnosed with diabetes.[33] After 25 years, the number with neuropathy rose to 45%. In the United Kingdom, the prevalence of diabetic neuropathy among the hospital clinic population was noted to be around 29%.[34]

Diabetic neuropathy in racial minorities

No definite racial predilection has been demonstrated for diabetic neuropathy. However, members of minority groups (eg, Hispanics, African Americans) have more secondary complications from diabetic neuropathy, such as lower-extremity amputations, than whites.[21] They also have more hospitalizations for neuropathic complications.

Sex differences in diabetic neuropathy

DM affects men and women with equal frequency. However, male patients with type 2 diabetes may develop diabetic polyneuropathy earlier than female patients,[35] and neuropathic pain causes more morbidity in females than in males.

Diabetic neuropathy and advancing age

Diabetic neuropathy can occur at any age but is more common with increasing age and severity and duration of diabetes.

Previous
Next

Prognosis

Patients with untreated or inadequately treated diabetes have higher morbidity and complication rates related to neuropathy than patients with tightly controlled diabetes. Repetitive trauma to affected areas may cause skin breakdown, progressive ulceration, and infection. Amputations and death may result.

Treating diabetic neuropathy is a difficult task for the physician and patient. Most of the medicines mentioned in the Medication section do not lead to complete symptom relief. Clinical trials are under way to help find new ways to treat symptoms and delay disease progression.

Mortality is higher in people with cardiovascular autonomic neuropathy (CAN). The overall mortality rate over periods up to 10 years was 27% in patients with DM and CAN detected, compared with a 5% mortality rate in those without evidence of CAN. Morbidity results from foot ulceration and lower-extremity amputation. These 2 complications are the most common causes of hospitalization among people with DM in Western countries. Severe pain, dizziness, diarrhea, and impotence are common symptoms that decrease the QOL of a patient with DM. In patients with diabetic peripheral neuropathy, the prognosis is good, but the patient's QOL is reduced.

For more information, go to Diabetic Foot.

for more information, go to Diabetic Foot Infections.

Previous
Next

Patient Education

Controlling diet and nutrition are paramount to improving the secondary complications of diabetes, including neuropathy. Patients with diabetic neuropathy should work with nutritionists or their primary care physicians to develop a realistic diet for lowering blood glucose and minimizing large fluctuations in blood glucose.

Patients with diabetic neuropathy should be encouraged to remain as active as possible. However, those with significant sensory loss or autonomic dysfunction should be cautioned about exercising in extreme weather conditions, which may result in injury. For example, patients with extremity numbness may not be aware of frostbite injuries during prolonged cold exposure, or those with abnormal sweating may become easily overheated in hot conditions. In most cases, consultation with the patient's regular physician is reasonable before the initiation of a regular exercise program.

Patients with diabetic neuropathy need to be educated on all aspects of their condition, and they need to know that it is very much affected by poor glycemic control. Prevention of diabetic neuropathy is potentially best achieved by having near-euglycemic control from the onset of DM. Even in patients with symptoms of diabetic neuropathy, controlling blood glucose to euglycemic levels reduces pain significantly. When a person has poor control and becomes euglycemic quickly, pain may be exacerbated (possibly due to an insulin effect), but this pain disappears in a few days. The bottom line for patients is that medications are imperfect. Many result in no pain relief for certain patients. However, glucose control is something that the patient can achieve that may reduce pain.

The importance of protection and care of insensitive feet cannot be overemphasized. Patients should be instructed to trim their toenails with great care and to be fastidious about foot hygiene. Any fungal or bacterial infection mandates prompt medical attention. The need for well-fitting shoes should be stressed.

Diabetic polyneuropathy is often associated with diabetic retinopathy and nephropathy. Patients with neuropathy should be counseled to seek appropriate eye care and discuss renal care and follow-up with their primary care physicians or endocrinologists.

Patient education should begin in the primary care office. The following outline reviews some common questions and answers that can serve as a springboard for discussion.

What is diabetic neuropathy?

Diabetic neuropathy is nerve damage caused by diabetes. In the United States, diabetes is one of the most common causes of nerve damage, also known as peripheral neuropathy. Diabetic neuropathy can affect nerves that supply feeling and movement in the arms and legs. It can also affect the nerves that regulate unconscious vital functions such as heart rate and digestion.

How does diabetic neuropathy occur?

Doctors have been studying this problem for many years, but they do not yet understand exactly how diabetes damages nerves. However, they have observed that good control of blood sugar levels helps prevent diabetic neuropathy and slows its progression, especially in patients with type 1 diabetes.

What are the symptoms?

Symptoms of diabetic neuropathy may include the following:

  • Numbness or loss of feeling (usually in the feet and legs first, then the hands)
  • Pain
  • Muscle weakness
  • Low blood pressure and dizziness when rising quickly from sitting or lying down
  • Rapid or irregular heartbeats
  • Trouble having an erection
  • Nausea or vomiting
  • Difficulty swallowing
  • Constipation or diarrhea

Pain from diabetic neuropathy may range from minor discomfort or tingling in toes to severe pain. Pain may be sharp or lightning-like, deep and aching, or burning. Extreme sensitivity to the slightest touch can also occur (allodynia).

How can I help prevent diabetic neuropathy?

The following steps may help to prevent or slow the worsening of diabetic neuropathy[36] :

  • Control diabetes; try to keep blood sugar at a normal level
  • Maintain normal blood pressure
  • Exercise regularly, according to the healthcare provider's recommendation
  • Stop smoking
  • Limit the amount of alcohol intake because excessive alcohol also can cause neuropathy or make it worse
  • Eat a healthy diet and avoid elevated levels of triglycerides in the blood
  • Maintain a healthy weight
  • Keep follow-up appointments with the healthcare provider

How is diabetic neuropathy treated?

No treatment is currently available to reverse neuropathy. The best approach is to control the diabetes and other risk factors.

Muscle weakness is treated with support, such as braces. Physical therapy and regular exercise may help patients maintain the muscle strength they have.

Pain medications may help make pain more tolerable. Medications can be used to treat nausea, vomiting, and diarrhea.

Men who have trouble having erections because of neuropathy should talk to their healthcare providers. Medications can help a man achieve and maintain an erection, or prosthetic devices can be put in the penis.

Preventing injuries such as burns, cuts, or broken bones is especially important, because patients with neuropathy have more complications from simple injuries and may not heal as quickly as healthy individuals.

How can I take care of myself?

Diabetes patients can take the following self-care measures:

  • Work with primary care physicians and endocrinologists to control glucose levels
  • Examine the skin of feet and lower legs regularly to look for injuries
  • See a healthcare provider promptly for calluses, sores on the skin, or other potential problems so they can be treated properly.
  • Wear good-fitting, comfortable shoes that protect the feet

How long will the problem last?

Once a person has neuropathy, the symptoms will persist indefinitely, but most people with diabetic neuropathy are able to lead active, fulfilling lives. Keeping blood sugar under good control may stop neuropathy from worsening.

For excellent patient education resources, visit eMedicine's Diabetes Center and Erectile Dysfunction Center. Also, see eMedicine's patient education articles, Diabetes and Diabetic Foot Care.

Previous
 
 
Contributor Information and Disclosures
Author

Helen C Lin, MD  Assistant Professor of Neurology, Medical College of Wisconsin, Milwaukee

Helen C Lin, MD is a member of the following medical societies: American Academy of Neurology and American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Dianna Quan, MD  Associate Professor of Neurology, Director, Electromyography Laboratory, University of Colorado School of Medicine

Dianna Quan, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa

Disclosure: e-medicine Honoraria Other

Specialty Editor Board

Milind J Kothari, DO  Professor and Vice-Chair, Department of Neurology, Pennsylvania State University College of Medicine; Consulting Staff, Department of Neurology, Penn State Milton S Hershey Medical Center

Milind J Kothari, DO is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Neurological Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Neil A Busis, MD  Chief, Division of Neurology, Department of Medicine, Head, Clinical Neurophysiology Laboratory, University of Pittsburgh Medical Center-Shadyside

Neil A Busis, MD is a member of the following medical societies: American Academy of Neurology and American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Chief Editor

Nicholas Lorenzo, MD  Consulting Staff, Neurology Specialists and Consultants

Nicholas Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, and American College of Physician Executives

Disclosure: Nothing to disclose.

References
  1. Boulton AJ, Malik RA. Diabetic neuropathy. Med Clin North Am. Jul 1998;82(4):909-29. [Medline].

  2. Bromberg MB. Peripheral neurotoxic disorders. Neurol Clin. Aug 2000;18(3):681-94. [Medline].

  3. Goetz CG, Pappert EJ. Textbook of Clinical Neurology. Philadelphia: WB Saunders Co; 1999.

  4. Pourmand R. Diabetic neuropathy. Neurol Clin. Aug 1997;15(3):569-76. [Medline].

  5. Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy--a continuing enigma. Diabetes Metab Res Rev. Nov-Dec 2000;16(6):408-33. [Medline].

  6. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia. Aug 2000;43(8):957-73. [Medline].

  7. Wilson JD. Williams Textbook of Endocrinology. 9th ed. Philadelphia: WB Saunders Co; 1998.

  8. Zochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol. Oct 2008;21(5):527-33. [Medline].

  9. Calcutt NA, Dunn JS. Pain: Nociceptive and Neuropathic Mechanisms. Anesthesiology Clinics of North America.; 1997.

  10. Malik RA. Pathology and pathogenesis of diabetic neuropathy. Diabetes Reviews. 1999;7:253-60.

  11. Shigeta H, Yamaguchi M, Nakano K, Obayashi H, Takemura R, Fukui M. Serum autoantibodies against sulfatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care. Dec 1997;20(12):1896-9. [Medline].

  12. Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B. VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep. Mar 30 2010;[Medline].

  13. Carrington AL, Litchfield JE. The aldose reductase pathway and nonenzymatic glycation in the pathogenesis of diabetic neuropathy: a critical review for the end of the 20th century. Diabetes Reviews. 1999.;7:275-99.

  14. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology. Aug 11 1999;53(3):580-91. [Medline].

  15. Ryle C, Donaghy M. Non-enzymatic glycation of peripheral nerve proteins in human diabetics. J Neurol Sci. Mar 1995;129(1):62-8. [Medline].

  16. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. Nov 2006;29(11):2365-70. [Medline].

  17. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. Dec 2008;9(4):301-14. [Medline].

  18. Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999;107(7):421-30. [Medline].

  19. Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology. Sep 1998;51(3):695-702. [Medline].

  20. Krendel DA, Zacharias A, Younger DS. Autoimmune diabetic neuropathy. Neurol Clin. Nov 1997;15(4):959-71. [Medline].

  21. Dorsey RR, Eberhardt MS, Gregg EW, Geiss LS. Control of risk factors among people with diagnosed diabetes, by lower extremity disease status. Prev Chronic Dis. Oct 2009;6(4):A114. [Medline]. [Full Text].

  22. Diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. Sep 30 1993;329(14):977-86. [Medline].

  23. Harati Y. Diabetes and the nervous system. Endocrinol Metab Clin North Am. Jun 1996;25(2):325-59. [Medline].

  24. Rutkove SB. A 52-year-old woman with disabling peripheral neuropathy: review of diabetic polyneuropathy. JAMA. Oct 7 2009;302(13):1451-8. [Medline].

  25. Finucane TE. Diabetic polyneuropathy and glucose control. JAMA. Feb 3 2010;303(5):420; author reply 420-1. [Medline].

  26. Boulton AJ, Malik RA. Neuropathy of impaired glucose tolerance and its measurement. Diabetes Care. Jan 2010;33(1):207-9. [Medline].

  27. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. Apr 1993;43(4):817-24. [Medline].

  28. Perkins BA, Olaleye D, Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care. Mar 2002;25(3):565-9. [Medline].

  29. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Reviews. 1999;7:245-52.

  30. Singh R, Gamble G, Cundy T. Lifetime risk of symptomatic carpal tunnel syndrome in Type 1 diabetes. Diabet Med. May 2005;22(5):625-30. [Medline].

  31. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. Feb 2000;47(2):123-8. [Medline].

  32. Dyck PJ, O'Brien PC. Quantitative sensation testing in epidemiological and therapeutic studies of peripheral neuropathy. Muscle Nerve. Jun 1999;22(6):659-62. [Medline].

  33. Pirart J. Diabetes mellitus and its degenerative complication: a prospective study of 4,400 patient observed between 1947 and 1973. Diabetes Care. 1978;1:168-188.

  34. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. Feb 1993;36(2):150-4. [Medline].

  35. Aaberg ML, Burch DM, Hud ZR, Zacharias MP. Gender differences in the onset of diabetic neuropathy. J Diabetes Complications. Mar-Apr 2008;22(2):83-7. [Medline].

  36. Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. Dec 21-28 1996;348(9043):1698-701. [Medline].

  37. Johnson DA, Vinik AI. Gastrointestinal Disturbances. In: Therapy for Diabetes Mellitus. American Diabetes Association; 1998.

  38. Ziegler D. Cardiovascular autonomic neuropathy: clinical manifestations and measurement. Diabetes Reviews. 1999;7:342-57.

  39. Meijer JW, van Sonderen E, Blaauwwiekel EE, et al. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care. Jun 2000;23(6):750-3. [Medline].

  40. Hokkam EN. Assessment of risk factors in diabetic foot ulceration and their impact on the outcome of the disease. Prim Care Diabetes. Nov 2009;3(4):219-24. [Medline].

  41. Coppini DV, Wellmer A, Weng C, Young PJ, Anand P, Sönksen PH. The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds. J Clin Neurosci. Nov 2001;8(6):520-4. [Medline].

  42. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. Feb 2001;24(2):250-6. [Medline].

  43. Dyck PJ, Turner DW, Davies JL, O'Brien PC, Dyck PJ, Rask CA. Electronic case-report forms of symptoms and impairments of peripheral neuropathy. Can J Neurol Sci. Aug 2002;29(3):258-66. [Medline].

  44. Biaggioni I. Postural hypotension. In: Therapy for Diabetes Mellitus. American Diabetes Association; 1998:423-30.

  45. Ayad H. Diabetic neuropathy: classification, clinical manifestations, diagnosis and management. In: Baba S et al, eds. Diabetes Mellitus in Asia. Amsterdam: Excerpta Medica; 1977:222-4.

  46. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. Sep 1997;46 Suppl 2:S54-7. [Medline].

  47. All About Diabetes. Date Accessed: October 30, 2008. American Diabetes Association. [Full Text].

  48. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: A report of the World Health Organization and International Diabetes Federation. Geneva, Switzerland: WHO Press; 2006.

  49. Abbott CA, Vileikyte L, Williamson S, et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care. Jul 1998;21(7):1071-5. [Medline].

  50. Llewelyn JG, Tomlinson DR, Thomas PK. Dyck PJ and Thomas PK. Diabetic Neuropathies in Peripheral Neuropathy. Philadelphia: Elsevier Saunders; 2005:1951-91.

  51. Lozeron P, Nahum L, Lacroix C, Ropert A, Guglielmi JM, Said G. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol. May 2002;249(5):569-75. [Medline].

  52. Waldman SD. Diabetic neuropathy: diagnosis and treatment for the pain management specialist. Curr Rev Pain. 2000;4(5):383-7. [Medline].

  53. Davidson MB. Diabetes Mellitus: Diagnosis and Treatment. 4th Ed. 1998:297-307.

  54. Vinik AI. New Methods to Assess Diabetic Neuropathy for Clinical Research.60th Scientific Sessions of the American Diabetes Association. American Diabetes Association; 2000.

  55. Tkac I, Bril V. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy. Diabetes Care. Oct 1998;21(10):1749-52. [Medline].

  56. Bril V. Electrophysiologic testing. In: Gries FA, Cameron NE, Low PA, Ziegler D. Textbook of Diabetic Neuropathy. Stuttgart, Germany: Thieme Medical Publishers; 2003:177-84.

  57. Huang CC, Chen TW, Weng MC, Lee CL, Tseng HC, Huang MH. Effect of glycemic control on electrophysiologic changes of diabetic neuropathy in type 2 diabetic patients. Kaohsiung J Med Sci. Jan 2005;21(1):15-21. [Medline].

  58. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. Jun 2006;29(6):1294-9. [Medline].

  59. Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med. Aug 30 1999;107(2B):34S-42S. [Medline].

  60. Apfel SC. Diabetic Polyneuropathy. In: Diabetes and Endocrinology Clinical Management. 1999.

  61. Argoff CE, Backonja MM, Belgrade MJ, Bennett GJ, Clark MR, Cole BE, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. Apr 2006;81(4 Suppl):S12-25. [Medline].

  62. Boulton A. Current and Emerging Treatments for Diabetic Neuropathies. Diabetes Reviews. 7:379-86.

  63. Slovenkai MP. Foot problems in diabetes. Med Clin North Am. Jul 1998;82(4):949-71. [Medline].

  64. O'Brien SP, Schwedler M, Kerstein MD. Peripheral neuropathies in diabetes. Surg Clin North Am. Jun 1998;78(3):393-408. [Medline].

  65. Skyler JS. Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am. Jun 1996;25(2):243-54. [Medline].

  66. Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care. Feb 2006;29(2):340-4. [Medline].

  67. Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. Jan 14 2003;60(1):108-11. [Medline].

  68. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. Mar 16 2011;CD007938. [Medline].

  69. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come?. Diabetes Care. Feb 2008;31 Suppl 2:S255-61. [Medline].

  70. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev. 2009;(4):CD007115. [Medline].

  71. [Best Evidence] Chou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med. Feb 2009;24(2):178-88. [Medline].

  72. Hayee MA, Mohammad QD, Haque A. Diabetic neuropathy and zinc therapy. Bangladesh Med Res Counc Bull. Aug 2005;31(2):62-7. [Medline].

  73. Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, et al. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine. J Diabetes Complications. Aug 26 2009;[Medline].

  74. Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications. Sep 10 2009;[Medline].

  75. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. Jul 2006;29(7):1538-44. [Medline].

  76. Ando H, Takamura T, Nagai Y, Kaneko S,. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy. J Diabetes Complications. Nov-Dec 2006;20(6):367-70. [Medline].

  77. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. Jan 27 2005;352(4):341-50. [Medline].

  78. Daousi C, Benbow SJ, MacFarlane IA. Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med. Apr 2005;22(4):393-8. [Medline].

  79. Ahn AC, Bennani T, Freeman R, Hamdy O, Kaptchuk TJ. Two styles of acupuncture for treating painful diabetic neuropathy--a pilot randomised control trial. Acupunct Med. Jun 2007;25(1-2):11-7. [Medline].

  80. Miller RD. Anesthesia. 5th ed. New York: Churchill Livingstone; 2000.

  81. Ferreira MC, Carvalho VF, Kamamoto F, Tuma P Jr, Paggiaro AO. Negative pressure therapy (vacuum) for wound bed preparation among diabetic patients: case series. Sao Paulo Med J. 2009;127(3):166-70. [Medline].

  82. Crouch J. Charcot's joint and bilateral foot neuropathy. Adv Nurse Pract. Mar 2005;13(3):18. [Medline].

  83. Pfeiffer MA, Schumer M. Painful or insensitive lower extremity. In: Therapy for Diabetes Mellitus. American Diabetes Association; 1998.

  84. Somers DL, Somers MF. Treatment of neuropathic pain in a patient with diabetic neuropathy using transcutaneous electrical nerve stimulation applied to the skin of the lumbar region. Phys Ther. Aug 1999;79(8):767-75. [Medline].

  85. [Guideline] Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. Prepublished online April 11, 2011;[Full Text].

  86. Tavakoli M, Kallinikos P, Iqbal A, et al. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med. Oct 2011;28(10):1261-7. [Medline]. [Full Text].

  87. Possidente CJ, Tandan R. A survey of treatment practices in diabetic peripheral neuropathy. Prim Care Diabetes. Nov 2009;3(4):253-7. [Medline].

  88. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. Dec 2 1998;280(21):1831-6. [Medline].

  89. Bennett GJ, Dworkin RH, Nicholson B. Anticonvulsant Therapy in the Treatment of Neuropathic Pain. In: Neurology Treatment Update. 2000.

  90. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology. Feb 2005;48(2):252-63. [Medline].

  91. [Best Evidence] Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. Aug 2009;32(8):1479-84. [Medline].

  92. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. Dec 14 2004;63(11):2104-10. [Medline].

  93. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. Apr 11 2011;[Medline].

  94. Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev. Jan 19 2011;CD005451. [Medline].

  95. FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs. U.S. Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149533.htm. Accessed May 16, 2000.

  96. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. Apr 2005;28(4):956-62. [Medline].

  97. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. Jun 1998;50(6):1842-6. [Medline].

  98. Jarvis B, Coukell AJ. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs. Oct 1998;56(4):691-707. [Medline].

Previous
Next
 
Table. Subdivisions of Sensory Neurons
Fiber Type Size Modality Myelination
A-alpha (I)13-20 micrometersLimb proprioceptionYes
A-beta (II)6-12 micrometersLimb proprioception, vibration, pressureYes
A-delta (III)1-5 micrometersMechanical sharp painYes
C (IV)0.2-1.5 micrometersThermal pain, mechanical burning painNo
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.